PDS Biotech Halts Phase 3 Trial, Pivots to PDS0301 After 71% ORR in Colorectal Cancer
PDSB sits 50% above its 52-week low of $0.507 on light trading volume (0.3× avg).
Summary
PDS Biotech is discontinuing the PDS0101 Phase 3 VERSATILE-003 trial and redirecting resources to PDS0301, an immunocytokine that showed a 71% objective response rate at 6 months and 80% 24-month survival in metastatic MSS/pMMR colorectal cancer with liver metastases. The company will seek a partner for PDS0101, citing capital constraints—this follows a recent Nasdaq deficiency notice and a $50M ATM program. The pivot concentrates the pipeline on a single asset with compelling Phase 2 data, but the company's $40M market cap and sub-$1 stock price underscore the urgency of the strategic shift. The next catalyst is advancement of PDS0301 into later-stage trials, though no timeline was provided.
Updates
· Benzinga — Shares fell 67% to $0.26, a 52-week low, with RSI at 17.90.
At the time of this announcement, PDSB was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.9M. The 52-week trading range was $0.51 to $1.55. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.